Results 191 to 200 of about 32,786 (220)
Some of the next articles are maybe not open access.
Therapy for immunoglobulin light chain amyloidosis: the new and the old
Blood Reviews, 2004An accurate diagnosis of amyloidosis and its subtype classification are essential for disease prognostication and treatment. In primary amyloidosis, overall median survival is approximately 2 years and may be less in patients with cardiomyopathy. Current therapy for primary amyloidosis is suboptimal.
Morie A Gertz +2 more
exaly +3 more sources
JACC Cardiovascular Imaging, 2020
OBJECTIVES This study aimed to test the diagnostic value of fludeoxyglucose F 18 ([18F])-florbetaben positron emission tomography (PET) in patients with suspicion of CA.
D. Genovesi +9 more
semanticscholar +1 more source
OBJECTIVES This study aimed to test the diagnostic value of fludeoxyglucose F 18 ([18F])-florbetaben positron emission tomography (PET) in patients with suspicion of CA.
D. Genovesi +9 more
semanticscholar +1 more source
Stem cell transplantation for immunoglobulin light chain amyloidosis
Current Problems in Cancer, 2017Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission.
Taimur, Sher, Morie A, Gertz
openaire +2 more sources
Immunoglobulin Light Chain and Systemic Light-Chain Amyloidosis
2007Light-chain amyloidosis (AL) is characterized by the clonal expansion of plasma B cells that secrete large amounts of monoclonal immunoglobulin light chains. The free light chains circulate in serum and form amyloid fibrils on vital organs such as the kidney, heart, and liver causing organ failure and eventually death.
Marina Ramirez-Alvarado +5 more
openaire +1 more source
Antibody‐based immunotherapy for treatment of immunoglobulin light‐chain amyloidosis
British Journal of Haematology, 2020SummaryImmunoglobulin light‐chain (AL) amyloidosis is a clonal plasma cell disorder characterised by production and deposition of misfolded monoclonal light chains in vital organs with potential to cause irreversible organ damage. The treatment of AL amyloidosis has evolved along the lines of multiple myeloma (MM) owing to clonal plasma cells being at ...
Ricardo D. Parrondo +2 more
openaire +2 more sources
Flow cytometry in immunoglobulin light chain amyloidosis: Short review
Leukemia Research, 2015Flow cytometry (FCM) has found its application in clinical diagnosis and evaluation of monoclonal gammopathies (MG). Although, research has been mainly focused on multiple myeloma (MM), nowadays FCM becomes to be potential tool in the field of AL amyloidosis.
Jana, Filipova +6 more
openaire +2 more sources
Diagnosis and Therapy of Immunoglobulin Light Chain Amyloidosis (AL Amyloidosis)
2012Amyloidosis is a group of disorders that have in common the deposition of protein fibrils composed of protofibrils that have a crystallographic β(beta)-pleated sheet structure. Disease results from these proteinaceous deposits in one or more organ systems [1].
Morie A. Gertz, Robert A. Kyle
openaire +1 more source
[Treatment strategy for immunoglobulin light chain amyloidosis].
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2021Systemic AL amyloidosis is a disease wherein amyloid proteins derived from monoclonal immunoglobulin light chains produced by abnormal plasma cells are deposited in the tissues through the whole body and cause organ failure. The treatment aims to minimize treatment-related toxicity and mortality to achieve a deeper and more persistent hematologic ...
openaire +1 more source